Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03729245 · ClinicalTrials.gov registry record · Phase 3
A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)
A Phase 3 study, sponsored by Nektar Therapeutics.
- Terminated
- Registry status
- Phase 3
- Development phase
- 623
- Enrollment target
NCT03729245 is a Phase 3 study that was terminated before completion, run by Nektar Therapeutics. The registered enrollment target is 623 participants.
The verdict
NCT03729245, a Phase 3 study, was terminated before completion, sponsored by Nektar Therapeutics.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 623 participants
- Enrollment target
Study Summary
The main purpose of this study is to compare the objective response rate (ORR) and overall survival (OS) of bempegaldesleukin (NKTR-214: BEMPEG) combined with nivolumab to that of tyrosine kinase inhibitor (TKI) monotherapy (sunitinib or cabozantinib) in IMDC intermediate- or poor-risk patients and IMDC all-risk patients with previously untreated advanced renal cell carcinoma (RCC).
Interventions
- BIOLOGICAL nivolumab
- DRUG sunitinib
- DRUG cabozantinib
- BIOLOGICAL bempegaldesleukin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 623 participants |
| Start Date | 2018-12-18 |
| Est. Completion | 2022-10-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03729245
The ClinicalTrials.gov registry entry for NCT03729245 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 623 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nektar Therapeutics, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which nivolumab is the first listed.
NCT03729245 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03729245 about?
NCT03729245 is a clinical study titled "A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)". The main purpose of this study is to compare the objective response rate (ORR) and overall survival (OS) of bempegaldesleukin (NKTR-214: BEMPEG) combined with nivolumab to that of tyrosine kinase inhibitor (TKI) monotherapy (sunitinib or cabozantinib) in IMDC intermediate- or poor-risk patients and ...
What is the current status of trial NCT03729245?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 623 participants. The study started on 2018-12-18. Estimated completion is 2022-10-19.
What interventions are being tested in trial NCT03729245?
The interventions under investigation include: nivolumab (BIOLOGICAL), sunitinib (DRUG), cabozantinib (DRUG), bempegaldesleukin (BIOLOGICAL).
Who is sponsoring clinical trial NCT03729245?
This trial is sponsored by Nektar Therapeutics, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.